https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54489 Wed 28 Feb 2024 16:31:52 AEDT ]]> Depression, anxiety, and stress among people with chronic hepatitis C virus infection and a history of injecting drug use in New South Wales, Australia https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33344 Wed 24 Nov 2021 15:52:58 AEDT ]]> Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: the ACTIVATE study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34079 Wed 17 Nov 2021 16:31:48 AEDT ]]> Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:16766 Wed 11 Apr 2018 15:18:46 AEST ]]> Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54918 Thu 21 Mar 2024 13:12:47 AEDT ]]> Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8319 Sat 24 Mar 2018 08:36:54 AEDT ]]> Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28384 Sat 24 Mar 2018 07:36:04 AEDT ]]> Barriers to the acceptance of work colleagues infected with Hepatitis B and Hepatitis C in Japan https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29344 Mon 08 Apr 2019 14:51:12 AEST ]]> Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49510 Fri 19 May 2023 16:56:03 AEST ]]> Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24132 24weeks post-treatment). Findings: Among 101 treated, 37% (n=37) had recently injected drugs (past 6months) and 62% (n=63) were receiving OST. Adherence =80% was 86% (n=87). SVR was 74% (75 of 101), with no difference observed by sex (males: 76%, females: 67%, P=0.662). In adjusted analysis, age <35 (versus =45years) [adjusted odds ratio (aOR)=5.06, 95% confidence interval (CI)=1.47, 17.40] and on-treatment adherence =80% independently predicted SVR (aOR=19.41, 95% CI=3.61, 104.26]. Recent injecting drug use at baseline was not associated with SVR. Conclusions: People with a history of injecting drug use and chronic hepatitis C virus attending opioid substitution treatment and community health clinics can achieve adherence and responses to interferon-based therapy similar to other populations, despite injecting drugs at baseline. Younger age and adherence are predictive of improved response to hepatitis C virus therapy.]]> Fri 01 Apr 2022 09:25:51 AEDT ]]>